Skip to main content

Q/C Technologies, Inc.

QCLS
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
SEC CIK
0001321834

No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Q/C Technologies, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of QCLS: Q2 2025 compared with Q3 2025
MeasureQ2 2025Of which not filed for Q3 2025Q3 2025Change
Holders33112−20
Shares531.7K6016.9K−514.7K (−96.8%)
Value$65.3K$8$69.8K+$4.50K (+6.9%)

1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (2)

Institutions that held Q/C Technologies, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to QCLS in Q3 2025
InstitutionSharesValue% of portfolio
Fifth Lane Capital, LP10,000$41.5K0.04%
Citigroup Inc5$210.00%

Sold out (22)

Institutions that held Q/C Technologies, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Not filed for Q3 2025 yet (1)

Institutions that held Q/C Technologies, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding QCLS in Q2 2025 that haven't filed for Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Legacy Investment Solutions, LLC60$8